ClinConnect ClinConnect Logo
Search / Trial NCT01224886

Age and Insulin Resistance

Launched by UNIVERSITY OF LAUSANNE · Oct 19, 2010

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Aging Insulin Resistance Ectopic Lipids Obesity Exercise Physical Activity Oxidative Capacity Diabetes Metabolic Syndrome

ClinConnect Summary

This clinical trial is studying how exercise affects insulin resistance, which is an important factor in the development of type 2 diabetes, especially in older adults. Insulin resistance happens when the body's cells do not respond well to insulin, leading to higher blood sugar levels. The trial will look at how exercise can help the body use fat more effectively and reduce harmful fat deposits in muscles and organs, which are linked to obesity and diabetes. Participants will include sedentary and highly trained individuals aged 60 to 80, with a Body Mass Index (BMI) between 18 and 40, who do not smoke and have normal or slightly impaired blood sugar levels.

If you choose to participate, you will undergo various tests to assess how your muscles, liver, and heart respond to exercise. It’s important to note that certain health conditions, like significant heart disease or uncontrolled high blood pressure, may prevent you from joining. Overall, this trial aims to find out whether improving fat usage through exercise can lead to better insulin sensitivity and help in the fight against diabetes in older adults.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 60-80
  • Sedentary or highly trained
  • BMI 18-40
  • Non-Smoker
  • Normal glucose tolerance or impaired glucose tolerance
  • Willingness to comply with the protocol
  • Exclusion Criteria:
  • Contraindication to moderate exercise or clinical conditions precluding from joining an exercise program, such as clinically significant cardiovascular disease, peripheral vascular disease, uncontrolled hypertension, neurological or orthopedic disease
  • Recent weight loss or weight gain
  • Known diabetes
  • Known drugs to affect glucose homeostasis such as nicotinic acid, glucocorticoids
  • Severe anemia or lipid disturbances, hepatic or renal disease
  • Recent history of cancer
  • Hypothyroidism
  • Recent hormone replacement therapy
  • Known allergy to lidocaine or other local anesthetic
  • Positive stress test
  • Active alcohol or substance abuse

About University Of Lausanne

The University of Lausanne, a prominent Swiss research institution, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in various fields, including medicine, biology, and public health, to conduct rigorous and ethically sound research. By fostering partnerships with local and international healthcare organizations, the University of Lausanne aims to translate scientific discoveries into effective therapies and interventions, ultimately enhancing health outcomes and contributing to the global medical community.

Locations

Bern, , Switzerland

Lausanne, , Switzerland

Patients applied

0 patients applied

Trial Officials

Francesca Amati, MD,PhD

Principal Investigator

University of Lausanne

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials